End-stage hip and knee joint disease
Conditions
Interventions
A:Intravenous use of 15mg / kg tranexamic acid
B:Periarticular injection of 15mg / kg tranexamic acid
Sponsors
Orthopeadic Department,Peking Union Medical College Hospital,Chinese Academy of Medical Science
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Patients plan to receive total hip or total knee arthroplasty due to end-stage hip and knee joint disease
Exclusion criteria
Exclusion criteria: (1) Patinets with history of venous thromboembolism, pulmonary embolism, cerebral infarction, coronary heart disease; (2) Patients with coagulation disorders; (3) Anticoagulant drugs are being used; (4) Administration of NSAID for less than 1 weeks; (5) TXA allergy; (6) Severe liver and renal insufficiency; (7) Patients with high risk of thrombosis, including atrial fibrillation, cardiac pacemaker, and stent implantation; (8) severe hip and knee deformity.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| blood loss;other safety indexes; | — |
Secondary
| Measure | Time frame |
|---|---|
| hidden blood loss;Inflammatory index;Drainage volume;complications;postoperative days required to straight leg elevation ;Thigh circumference;postoperative days required to stand ; | — |
Countries
China
Contacts
Public ContactWENG Xisheng
Orthopedic Department, Peking Union Medical College Hospital,Chinese Academy of Medical Science
Outcome results
None listed